Cytopenias Are ‘Limited’ Following Ide-Cel in R/R Multiple Myeloma
The safety profile of idecabtagene vicleucel in relapsed/refractory multiple myeloma following the first 3 months of treatment appears to be comparable with standard therapies, says Rachid Baz, MD.
Multiple Myeloma: Unmet Needs and Future Perspectives
Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.
Patient Profile 3: Patient With MM Progressing After Several Prior Therapies
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider use of CAR T-cell therapy or bispecifics in this setting.
CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Shared insight on the development of CAR T-cell therapies and their use in the later-line setting for patients with multiply relapsed multiple myeloma.
Bispecifics-Based Combination Therapy in Multiple Myeloma
Expert perspectives on the combination of novel bispecific therapies and where they may fit into the treatment paradigm of relapsed/refractory multiple myeloma.
Experts Discuss SOC for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Current standard of care options in transplant-eligible, newly diagnosed multiple myeloma have been outlined in groundbreaking trials, of which a group of experts convened to discuss the best treatment options.
Non-BCMA Targeting Therapies in Multiple Myeloma
A brief review of talquetamab, a novel agent in the setting of relapsed/refractory multiple myeloma that targets GPRC5D.
BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma
Following their discussion on teclistamab, experts from the Moffit Cancer Center highlight other BCMA-targeted therapies available in the relapsed/refractory setting of multiple myeloma.
Bispecifics in the Treatment of Multiple Myeloma: Teclistamab
Panelists review data from the MajesTEC-1 clinical trial and elucidate the role of teclistamab therapy in patients with relapsed/refractory multiple myeloma.
Sequencing Therapies in Relapsed/Refractory Multiple Myeloma
Shared insight on the value of using effective regimens upfront and optimal sequencing throughout several lines of therapy in multiple myeloma.
Relapsed/Refractory Multiple Myeloma: Overview of Treatment Options
Switching their focus to the relapsed/refractory setting, experts from the Moffit Cancer Center consider second-line treatment options for patients with multiple myeloma.
Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert perspectives on a patient profile of transplant-ineligible multiple myeloma, with considerations for treatment selection and defining transplant ineligibility.
Treatment Duration in Patients With Transplant-Ineligible NDMM
Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.
Transplant-Ineligible NDMM: Optimizing Therapy for Frailer Patients
Experts from the Moffit Cancer Center work to identify frail patients with transplant-ineligible NDMM and consider how best to select first-line therapy for this population.
Selecting First-Line Therapy for Patients With Transplant-Ineligible NDMM
Moving on to review the management of transplant-ineligible NDMM, expert panelists highlight first-line treatment options with data from the SWOG0777 and MAIA studies.
Patient Profile 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering focus on a patient scenario of transplant-eligible newly diagnosed multiple myeloma, panelists consider the role of induction therapy and transplant in this setting.
Selection of Induction Therapy in Patients With Transplant-Eligible NDMM
Shared insight from experts in multiple myeloma on the real-world utilization of induction therapy and transplant for patients with newly diagnosed disease.
Transplant-Eligible NDMM: Overview of Available Induction Therapies
Experts from the Moffit Cancer Center share insight on induction therapy strategies and optimization for patients with transplant-eligible newly diagnosed multiple myeloma.
2 Commerce Drive Cranbury, NJ 08512